月別アーカイブ: 2015年2月

Flex Pharma Presenting at Three Upcoming Investor Conferences in March 2015

BOSTON–(BUSINESS WIRE)–

Flex Pharma, Inc. (FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that it will present a corporate overview at the following upcoming investor conferences in March:

  • The 35th Annual Cowen and Company Healthcare Conference on March 4, 2015 at 9:20 a.m. ET in Boston, MA;
  • The 27th Annual Roth Conference on March 10, 2015 at 11:30 a.m. PT in Dana Point, CA; and
  • The Barclays Capital Healthcare Conference on March 12, 2015 at 2:35 p.m. ET in Miami, FL.

A live webcast of Flex Pharma’s presentations at these conferences may be accessed in the Investor section of the Company’s website at www.flex-pharma.com. Please log on to the Flex Pharma website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Flex Pharma’s website for 2 weeks following each presentation.

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma’s proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers.

Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.

Contact:
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
VP, Investor Relations & Corporate Communications
irdept@flex-pharma.com

Source Article from http://finance.yahoo.com/news/flex-pharma-presenting-three-upcoming-133000757.html
Flex Pharma Presenting at Three Upcoming Investor Conferences in March 2015
http://finance.yahoo.com/news/flex-pharma-presenting-three-upcoming-133000757.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results



Biogenesis chemist Paulo Berejuk gets 18 months in prison

 

A chemist working out of his suburban South Florida garage was sentenced Wednesday to 18 months in prison for supplying banned performance-enhancing substances to a clinic whose customers included professional baseball players such as New York Yankees star Alex Rodriguez.

Paulo Berejuk had hoped for probation and home confinement after pleading guilty in December to conspiracy to distribute testosterone. But U.S. District Judge Cecilia M. Altonaga agreed with prosecutors that Berejuk’s role in the case was too vital and his cooperation with investigators too limited to warrant such a sentencing break.

”I cannot in good faith sentence Mr. Berejuk to probation,” Altonaga said at a hearing. ”This involved a serious crime. I have to consider deterrence to others.”

Investigators said Berejuk was the key drug source for Anthony Bosch, who ran the now-closed Biogenesis of America clinic in Coral Gables that sold steroids to baseball players and other athletes, some only in high school. Berejuk admitted in court documents that between 2007 and 2013 he supplied up to 10,000 units of steroids to Bosch and others for as much as $20,000 a month.

”This defendant is one of the most important people in the conspiracy,” said Assistant U.S. Attorney Sharad Motiani.

The doping scandal resulted in suspensions last year for 14 professional baseball players and criminal convictions for Bosch and others. Rodriguez, who got the stiffest Major League Baseball suspension at a full season, recently apologized to Yankee fans in a written statement and previously admitted in interviews with U.S. Drug Enforcement Administration agents that he used Bosch-supplied steroids.

Rodriguez also would be a key government witness if the remaining two people charged in the case – Rodriguez cousin Yuri Sucart and former University of Miami baseball coach Lazaro Collazo – go to trial as scheduled April 6. Both have pleaded not guilty to drug conspiracy charges.

Berejuk, 51, apologized in court for his actions but said he took full responsibility. Berejuk faces possible deportation to his native Brazil after serving his prison sentence.

”I really regret what I did, but no excuses. I recognize when I’m wrong,” he said.

MORE: For the diehard fans: Check out Just a Bit Outside.

Source Article from http://www.foxsports.com/mlb/story/biogenesis-chemist-paulo-berejuk-sentenced-to-18-months-in-prison-for-supplying-peds-022515
Biogenesis chemist Paulo Berejuk gets 18 months in prison
http://www.foxsports.com/mlb/story/biogenesis-chemist-paulo-berejuk-sentenced-to-18-months-in-prison-for-supplying-peds-022515
http://news.search.yahoo.com/news/rss?p=chemist
chemist – Yahoo News Search Results
chemist – Yahoo News Search Results



How to arrive at valuations for big pharma

What it means to be ‘big pharma’ in a $980 billion industry (Part 9 of 10)

(Continued from Part 8)

Mitigating patent expiration impact

When patents have expired in the last decade, big pharma companies have had to make various changes to their business models. Companies now work continuously on new drug development to ensure consistent cash flow and minimal effect of patent expiration.

While overall industry trends impact big pharma to an extent, there are other considerations that determine valuation for these companies:

  • existing patent rights
  • research pipeline and drugs in development
  • mergers and acquisitions executed or in the pipeline

 

The above chart shows the trend in forward EV/EBIDTA multiples (enterprise value to earnings before interest, depreciation, taxes, and amortization) for big pharma stocks over five years.

How valuation works

EV/EBITDA is often used to value capital-intensive companies. A forward EV/EBIDTA multiple is one way to represent a company’s valuation over the next twelve months. Bristol-Myers Squibb (BMY) has the highest EV/EBIDTA multiple, followed by Eli Lilly and Company (LLY).

Price-to-earnings

The price-to-earnings multiple is one of the simplest multiples used for valuations. Put simply, it represents the price of a stock per unit earning per share—that is, the price an investor pays to earn unit return. Forward PE is the estimated of PE multiple for the next twelve months. The PE ratio for global big pharma increased from 14.9x in 2011 to 26x in 2014. This trend is a measure of increasing investor confidence.

Free cash flow yield

To calculate free cash flow yield, you divide free cash flow by market capitalization. Generally, the lower the ratio, the less attractive the investment. The free cash flow yield for global big pharma fell from 7.5x in 2011 to 4.6x in 2014. This was caused by increased R&D (research and development) costs and reduced profit margins due to the patent expiry of a few major drugs.

Price-to-earnings-to-growth ratio

To calculate PE-to-growth, or PEG, ratio, you divide the PE multiple by the growth of an industry during a given period. For global big pharma, the PEG ratio rose from 1.5x in 2011 to 2.6x in 2014.

Johnson & Johnson (JNJ), Merck (MRK), Pfizer (PFE), and Bristol-Myers Squibb (BMY) combined form 24.81% of the Market Vectors Pharmaceutical ETF (PPH). Another of the ETFs in this sector is the SPDR S&P Pharmaceuticals ETF (XPH).

Continue to Part 10

Browse this series on Market Realist:

Source Article from http://finance.yahoo.com/news/arrive-valuations-big-pharma-200542995.html
How to arrive at valuations for big pharma
http://finance.yahoo.com/news/arrive-valuations-big-pharma-200542995.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results